Claritev (CTEV) Investor Day 2026 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2026 summary
20 Mar, 2026Strategic vision and transformation
Pursuing a multi-year transformation focused on transparency, affordability, and access, with a unique network and technology-driven approach to reduce friction in healthcare.
Vision 2030 targets long-term growth, innovation, and expansion into new markets, supported by a refreshed leadership team, rebranding, and five new market verticals.
Investing $20M–$35M annually in technology modernization through 2028, aiming for a 30–35% economic return post-transformation.
Prioritizing organic investments, debt paydown, and value-creating M&A to fuel Vision 2030, with capital allocation focused on tech investment and deleveraging.
Targeting sustained growth, diversified markets, and a scalable, data-driven operating model, with reduced reliance on top 10 customers by 10–12% over 18 months.
Product innovation and AI strategy
Launched and expanded BenInsights and CompleteVue platforms, with 30+ new features and 18+ new solutions planned, focusing on actionable analytics, claims intelligence, and risk management.
AI and machine learning are embedded across products and operations, with over 50 models in production, driving automation, predictive analytics, and operational efficiency.
AI-driven tools like ProPricer and Surprise Bill Services deliver higher negotiation success rates and automate manual processes, improving productivity and client outcomes.
Technology modernization, including migration to Oracle Cloud, has improved performance, enabled real-time data access, and is expected to yield a 30–35% economic return.
Continued investment in technology and AI to accelerate innovation and expand into underpenetrated markets, with a product roadmap centered on AI and data analytics.
Financial guidance and growth outlook
FY 2026 revenue guidance is $980M–$1B, with adjusted EBITDA of $605M–$615M and capital spend of $160M–$170M.
Projecting 4–6% revenue CAGR through 2028, with adjusted EBITDA margin of 61–62% and a long-term goal to achieve the Rule of 70 by 2030.
Levered free cash flow expected to rise from $0–$10M in 2026 to over $225M by 2030, with net leverage declining from 7.5x to ~5.0x.
Revenue mix is shifting toward more diversified, recurring streams, with PSAV revenue declining as a percentage but remaining a core, high-margin business.
Bookings reached $67.3M in 2025, with 30% from new clients and 70% from upsell/cross-sell, and a growing sales funnel supporting future revenue conversion.
Latest events from Claritev
- Definitive additional proxy materials outline voting procedures for the upcoming meeting.CTEV
Proxy filing20 Mar 2026 - Board recommends all proxy proposals amid strong 2025 results and governance enhancements.CTEV
Proxy filing20 Mar 2026 - Record bookings, robust AI-driven growth, and disciplined investment fuel expansion.CTEV
Status update6 Mar 2026 - Revenue and EBITDA grew, losses narrowed, and 2026 outlook includes buybacks and expansion.CTEV
Q4 202523 Feb 2026 - Q2 2024 net loss was $576.7M on $233.5M revenue, driven by a $553.7M impairment.CTEV
Q2 20242 Feb 2026 - Q3 2024 net loss surged on a $361.6M impairment as revenue fell 5.1% year-over-year.CTEV
Q3 202416 Jan 2026 - Transformation, tech investment, and data-driven strategy fuel growth and innovation in healthcare.CTEV
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - 2024 revenue declined 3.2% and net loss spiked on impairment as transformation accelerates.CTEV
Q4 202423 Dec 2025 - Healthcare cost management firm files to offer up to $400M in securities for growth and operations.CTEV
Registration Filing16 Dec 2025